TW201925204A - 稠合三環化合物 - Google Patents
稠合三環化合物 Download PDFInfo
- Publication number
- TW201925204A TW201925204A TW107141391A TW107141391A TW201925204A TW 201925204 A TW201925204 A TW 201925204A TW 107141391 A TW107141391 A TW 107141391A TW 107141391 A TW107141391 A TW 107141391A TW 201925204 A TW201925204 A TW 201925204A
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- alkyl
- methyl
- mmol
- group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017225151 | 2017-11-22 | ||
| JP2017-225151 | 2017-11-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW201925204A true TW201925204A (zh) | 2019-07-01 |
Family
ID=66631976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW107141391A TW201925204A (zh) | 2017-11-22 | 2018-11-21 | 稠合三環化合物 |
Country Status (2)
| Country | Link |
|---|---|
| TW (1) | TW201925204A (fr) |
| WO (1) | WO2019103060A1 (fr) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021238963A1 (fr) * | 2020-05-28 | 2021-12-02 | 杭州中美华东制药有限公司 | Procédé de préparation de sel de diacide de propanoate de méthyle (s)-2-amino-3-(4-(2,3-diméthylpyridine-4-yl)phényl) |
| WO2021238965A1 (fr) * | 2020-05-28 | 2021-12-02 | 杭州中美华东制药有限公司 | Procédé de préparation de méthyl (s)-2-amino-3-(4-(2,3-diméthylpyridin-4-yl)phénylpropionate et son sel |
| WO2022262143A1 (fr) * | 2021-06-17 | 2022-12-22 | 杭州中美华东制药有限公司 | Procédé de préparation de borate de pyridine |
| WO2025189141A1 (fr) | 2024-03-08 | 2025-09-12 | Annapurna Bio, Inc. | Méthodes de traitement de l'obésité et d'augmentation de la perte de poids |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115667268B (zh) * | 2020-05-28 | 2024-09-24 | 杭州中美华东制药有限公司 | 一种glp-1受体激动剂游离碱的制备方法 |
| US20240374587A1 (en) | 2021-09-08 | 2024-11-14 | Shionogi & Co., Ltd. | Medicine for prevention and treatment of diseases linked to anti-obesity activity |
| WO2025057134A2 (fr) | 2023-09-14 | 2025-03-20 | Ascletis Pharma (China) Co., Limited | Agoniste de glp-1r et méthode thérapeutique associée |
| US12291530B1 (en) | 2023-11-24 | 2025-05-06 | Ascletis Pharma (China) Co., Limited | GLP-1R agonist and therapeutic method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1147094A1 (fr) * | 1999-01-15 | 2001-10-24 | Novo Nordisk A/S | Agonistes non peptidiques de glp-1 |
| WO2009111700A2 (fr) * | 2008-03-07 | 2009-09-11 | Transtech Pharma, Inc. | Oxadiazoanthracènes pour le traitement du diabète |
| BRPI1013579A2 (pt) * | 2009-03-30 | 2020-11-03 | Transtech Pharma, Inc. | derivados de azoantraceno substituídos, composições farmacêuticas e métodos de uso dos mesmos |
-
2018
- 2018-11-21 WO PCT/JP2018/043065 patent/WO2019103060A1/fr not_active Ceased
- 2018-11-21 TW TW107141391A patent/TW201925204A/zh unknown
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021238963A1 (fr) * | 2020-05-28 | 2021-12-02 | 杭州中美华东制药有限公司 | Procédé de préparation de sel de diacide de propanoate de méthyle (s)-2-amino-3-(4-(2,3-diméthylpyridine-4-yl)phényl) |
| WO2021238965A1 (fr) * | 2020-05-28 | 2021-12-02 | 杭州中美华东制药有限公司 | Procédé de préparation de méthyl (s)-2-amino-3-(4-(2,3-diméthylpyridin-4-yl)phénylpropionate et son sel |
| CN115667219A (zh) * | 2020-05-28 | 2023-01-31 | 杭州中美华东制药有限公司 | 一种(s)-2-氨基-3-(4-(2,3-二甲基吡啶-4-基)苯基)丙酸甲酯二酸盐的制备方法 |
| CN115697968A (zh) * | 2020-05-28 | 2023-02-03 | 杭州中美华东制药有限公司 | (s)-2-氨基-3-(4-(2,3-二甲基吡啶-4-基)苯基丙酸甲酯及其盐的制备方法 |
| CN115697968B (zh) * | 2020-05-28 | 2024-03-29 | 杭州中美华东制药有限公司 | (s)-2-氨基-3-(4-(2,3-二甲基吡啶-4-基)苯基丙酸甲酯及其盐的制备方法 |
| WO2022262143A1 (fr) * | 2021-06-17 | 2022-12-22 | 杭州中美华东制药有限公司 | Procédé de préparation de borate de pyridine |
| WO2025189141A1 (fr) | 2024-03-08 | 2025-09-12 | Annapurna Bio, Inc. | Méthodes de traitement de l'obésité et d'augmentation de la perte de poids |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019103060A1 (fr) | 2019-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW201925204A (zh) | 稠合三環化合物 | |
| EP4025574B1 (fr) | Composés inhibiteurs de rip1 et leurs procédés de fabrication et d'utilisation | |
| TWI858848B (zh) | ErbB受體抑制劑 | |
| CN112979524B (zh) | 作为雌激素受体调节剂的6,7-二氢-5h-苯并[7]轮烯衍生物 | |
| CN105636953B (zh) | 1,4‑二取代的哒嗪衍生物及其用于治疗与smn缺乏相关的病症的用途 | |
| CN118647620A (zh) | 用于治疗癌症的环状2-氨基-3-氰基噻吩及其衍生物 | |
| WO2023046034A1 (fr) | Composé hétérocyclique contenant de l'azote, son procédé de préparation, intermédiaire de celui-ci et application de celui-ci | |
| WO2020064002A1 (fr) | Composé d'isoindoline, procédé de préparation, composition pharmaceutique et utilisation associée | |
| WO2018143315A1 (fr) | Composé de quinazoline | |
| WO2015158310A1 (fr) | Inhibiteur de tyrosine kinase et ses utilisations | |
| CN118221685A (zh) | 作为kras g12d抑制剂的吲哚类化合物 | |
| TW202045512A (zh) | 新型雜環三環衍生物化合物及其用途 | |
| WO2016169504A1 (fr) | Dérivé pyrimidylamino à cycle condensé, son procédé de préparation, et intermédiaire, composition pharmaceutique et applications associées | |
| WO2022100623A1 (fr) | Composés thiophène hétérocycliques substitués par azote et leur utilisation | |
| TW201602105A (zh) | 雜環化合物 | |
| TW201625533A (zh) | Kcnq 2至5通道活化劑 | |
| KR20220018475A (ko) | Ep300 또는 cbp 조절 및 이의 표시를 위한 응축 아진 | |
| TW202430522A (zh) | 一種用於bcl-2蛋白靶向降解的嵌合體化合物、其製備方法及其在醫藥上的應用 | |
| WO2020103769A1 (fr) | Composés de dioxane-quinazoline ou dioxane-quinoléine liés à un cycle aromatique, compositions et utilisation associées | |
| TWI691332B (zh) | 噻唑烷酮化合物及其用途 | |
| WO2019192533A1 (fr) | Agent de dégradation du récepteur des œstrogènes pour le traitement du cancer du sein | |
| WO2019129114A1 (fr) | Inhibiteurs de l'indoléamine 2,3-dioxygénase et leur utilisation en médecine | |
| WO2021115495A1 (fr) | Composé hétérocyclique contenant du soufre à petites molécules | |
| BR112021009378A2 (pt) | espiro-compostos heterocíclicos como inibidores de receptor de am2 | |
| WO2023098825A1 (fr) | Inhibiteur de sos1, composition pharmaceutique le comprenant et son utilisation |